Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

about

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

Item

http://www.wikidata.org/entity/Q39610381

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Antitumor activity of sorafeni ...... xon 13 missense mutation K642E

@en

Antitumor activity of sorafeni ...... on 13 missense mutation K642E.

@nl

type

Item

label

Antitumor activity of sorafeni ...... xon 13 missense mutation K642E

@en

Antitumor activity of sorafeni ...... on 13 missense mutation K642E.

@nl

prefLabel

Antitumor activity of sorafeni ...... xon 13 missense mutation K642E

@en

Antitumor activity of sorafeni ...... on 13 missense mutation K642E.

@nl

P1476

Antitumor activity of sorafeni ...... xon 13 missense mutation K642E

@en

P2093

Chiara Catania

http://www.w3.org/2001/XMLSchema#string

Chiara Lazzari

http://www.w3.org/2001/XMLSchema#string

Cristina Noberasco

http://www.w3.org/2001/XMLSchema#string

Fabio Conforti

http://www.w3.org/2001/XMLSchema#string

Filippo de Marinis

http://www.w3.org/2001/XMLSchema#string

Francesca Toffalorio

http://www.w3.org/2001/XMLSchema#string

Gianluca Spitaleri

http://www.w3.org/2001/XMLSchema#string

Massimo Barberis

http://www.w3.org/2001/XMLSchema#string

Michela Manzotti

http://www.w3.org/2001/XMLSchema#string

Tommaso Martino De Pas

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.

Somatic activation of KIT in distinct subtypes of melanoma.

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

P304

697-702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2147/OTT.S58902

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lorenzo Preda

P577

2014-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24855380

http://www.w3.org/2001/XMLSchema#string

P932

4020909

http://www.w3.org/2001/XMLSchema#string